Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

By R. Phillips, William Y. Shi, M. Deek, N. Radwan, S. Lim, E. Antonarakis, S. Rowe, A. Ross, M. Gorin, C. Deville and 16 more. JAMA Oncology, 2020

1,007 citations recorded by the source corpus.

This randomized clinical trial assesses whether treatment with stereotactic ablative radiotherapy vs observation improves oncologic outcomes in men with recurrent hormone-sensitive oligometastatic prostate cancer.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/83de16b1d106ad3fc9c5ad8aec164a80ba2f77de

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. N. Mottet
2. Thomas Wiegel

Citations in the corpus

• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “Recently, in a phase II study [87], 54 men were randomised 2:1 to sereotactic ablative radiotherapy (SABR) or observation.”